Pitchai Balakumar

List of Publications by Year
in descending order

87 papers	3,495 citations	126907 33 h-index	149698 56 g-index
87 all docs	87 docs citations	87 times ranked	4984 citing authors

#	Article	IF	Citations
1	Prevalence and prevention of cardiovascular disease and diabetes mellitus. Pharmacological Research, 2016, 113, 600-609.	7.1	381
2	Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it?. Pharmacological Research, 2010, 62, 179-186.	7.1	198
3	PPAR dual agonists: Are they opening Pandora's Box?. Pharmacological Research, 2007, 56, 91-98.	7.1	168
4	A century old reninâ€"angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cellular Signalling, 2014, 26, 2147-2160.	3.6	143
5	Arsenic Exposure and Cardiovascular Disorders: An Overview. Cardiovascular Toxicology, 2009, 9, 169-176.	2.7	137
6	The multifaceted therapeutic potential of benfotiamine. Pharmacological Research, 2010, 61, 482-488.	7.1	93
7	Multifarious molecular signaling cascades of cardiac hypertrophy: Can the muddy waters be cleared?â˜†. Pharmacological Research, 2010, 62, 365-383.	7.1	86
8	Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?. Journal of Molecular and Cellular Cardiology, 2012, 52, 83-92.	1.9	83
9	Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Molecular and Cellular Biochemistry, 2009, 320, 149-62.	3.1	73
10	Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders?. Pharmacological Research, 2009, 60, 361-368.	7.1	69
11	Submaximal PPARÎ³ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. British Journal of Pharmacology, 2012, 166, 1981-1992.	5.4	69
12	Fish oil and vascular endothelial protection: Bench to bedside. Free Radical Biology and Medicine, 2012, 53, 271-279.	2.9	68
13	Pathophysiology of Diabetic Nephropathy: Involvement of Multifaceted Signalling Mechanism. Journal of Cardiovascular Pharmacology, 2009, 54, 129-138.	1.9	66
14	Antiâ€Tumour Necrosis Factorâ€Î± Therapy in Heart Failure: Future Directions. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 391-397.	2.5	65
15	The impairment of preconditioning-mediated cardioprotection in pathological conditions. Pharmacological Research, 2009, 60, 18-23.	7.1	62
16	Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor. Journal of Molecular Endocrinology, 2014, 53, R71-R92.	2.5	62
17	Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions. Toxicology, 2008, 245, 49-64.	4.2	61
18	PPAR Ligands: Are They Potential Agents for Cardiovascular Disorders?. Pharmacology, 2007, 80, 1-10.	2.2	60

#	Article	IF	Citations
19	Vascular endothelial dysfunction: A tug of war in diabetic nephropathy?. Biomedicine and Pharmacotherapy, 2009, 63, 171-179.	5.6	59
20	Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacological Research, 2009, 60, 24-32.	7.1	58
21	Pre-conditioning and postconditioning to limit ischemiaâ€“reperfusion-induced myocardial injury: What could be the next footstep?. Pharmacological Research, 2008, 57, 403-412.	7.1	53
22	Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel?. Pharmacological Research, 2014, 87, 144-150.	7.1	49
23	A step ahead of PPARÎ³ full agonists to PPARÎ³ partial agonists: Therapeutic perspectives in the management of diabetic insulin resistance. European Journal of Pharmacology, 2015, 755, 50-57.	3.5	49
24	Interplay between statins and PPARs in improving cardiovascular outcomes: a doubleâ€edged sword?. British Journal of Pharmacology, 2012, 165, 373-379.	5.4	48
25	Healing the diabetic heart: Does myocardial preconditioning work?. Cellular Signalling, 2012, 24, 53-59.	3.6	48
26	Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?. Pharmacological Research, 2012, 65, 430-436.	7.1	47
27	The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy. European Journal of Pharmacology, 2010, 636, 137-144.	3.5	44
28	Cardiovascular and Renal Pathologic Implications of Prorenin, Renin, and the (Pro)renin Receptor: Promising Young Players From the Old Renin-Angiotensin-Aldosterone System. Journal of Cardiovascular Pharmacology, 2010, 56, 570-579.	1.9	42
29	Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacological Research, 2008, 58, 356-363.	7.1	40
30	Resident Cardiac Mast Cells: Are They the Major Culprit in the Pathogenesis of Cardiac Hypertrophy?. Basic and Clinical Pharmacology and Toxicology, 2008, 102, 5-9.	2.5	37
31	Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats. International Journal of Cardiology, 2008, 128, 383-391.	1.7	37
32	Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacological Research, 2009, 60, 170-173.	7.1	37
33	The Possible Role of Caspaseâ€3 in Pathological and Physiological Cardiac Hypertrophy in Rats. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 418-424.	2.5	36
34	Effect of Mast Cell Stabilizers in Hyperhomocysteinemia-induced Cardiac Hypertrophy in Rats. Journal of Cardiovascular Pharmacology, 2008, 51, 596-604.	1.9	35
35	A potential role of the renin-angiotensin-aldosterone system in epithelial-to-mesenchymal transition-induced renal abnormalities: Mechanisms and therapeutic implications. Pharmacological Research, 2019, 146, 104314.	7.1	34
36	Pleiotropic actions of fenofibrate on the heart. Pharmacological Research, 2011, 63, 8-12.	7.1	32

#	Article	IF	Citations
37	Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy. European Journal of Pharmacology, 2013, 698, 388-396.	3.5	32
38	Nephroprotective effect of catechin on gentamicin-induced experimental nephrotoxicity. Clinical and Experimental Nephrology, 2015, 19, 178-184.	1.6	32
39	Preconditioning the hyperlipidemic myocardium: Fact or fantasy?. Cellular Signalling, 2012, 24, 589-595.	3.6	30
40	Ameliorative Effect of Combination of Fenofibrate and Rosiglitazone in Pressure Overload-Induced Cardiac Hypertrophy in Rats. Pharmacology, 2007, 80, 177-184.	2.2	27
41	Differential Role of Rho-Kinase in Pathological and Physiological Cardiac Hypertrophy in Rats. Pharmacology, 2006, 78, 91-97.	2.2	26
42	The Novel Role of Fenofibrate in Preventing Nicotine- and Sodium Arsenite-Induced Vascular Endothelial Dysfunction in the Rat. Cardiovascular Toxicology, 2010, 10, 227-238.	2.7	26
43	Catechin Averts Experimental Diabetes Mellitus-Induced Vascular Endothelial Structural and Functional Abnormalities. Cardiovascular Toxicology, 2014, 14, 41-51.	2.7	26
44	Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials. Cellular Signalling, 2013, 25, 1799-1803.	3.6	25
45	Adenosine Transport Blockade Restores Attenuated Cardioprotective Effects of Adenosine Preconditioning in the Isolated Diabetic Rat Heart: Potential Crosstalk with Opioid Receptors. Cardiovascular Toxicology, 2013, 13, 22-32.	2.7	24
46	Low-dose dipyridamole treatment partially prevents diabetes mellitus-induced vascular endothelial and renal abnormalities in rats. International Journal of Cardiology, 2014, 172, 530-532.	1.7	24
47	Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders. Hypertension Research, 2011, 34, 1161-1170.	2.7	23
48	A Contemporary Overview of PPARÎ±/Î³ Dual Agonists for the Management of Diabetic Dyslipidemia. Current Molecular Pharmacology, 2019, 12, 195-201.	1.5	23
49	Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits. Pharmacological Research, 2019, 144, 132-141.	7.1	23
50	Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets. Pharmacological Research, 2020, 161, 105209.	7.1	22
51	Do resident renal mast cells play a role in the pathogenesis of diabetic nephropathy?. Molecular and Cellular Biochemistry, 2009, 330, 187-192.	3.1	20
52	Telmisartan in the Management of Diabetic Nephropathy: A Contemporary View. Current Diabetes Reviews, 2012, 8, 183-190.	1.3	20
53	Dapagliflozin: Glucuretic action and beyond. Pharmacological Research, 2014, 82, 34-39.	7.1	18
54	Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats. Pharmacological Research, 2014, 90, 36-47.	7.1	18

#	Article	IF	Citations
55	Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Archives of Pharmacal Research, 2010, 33, 611-618.	6.3	17
56	Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated. Pharmacological Research, 2015, 102, 81-89.	7.1	17
57	Effects of pre and post-treatments with dipyridamole in gentamicin-induced acute nephrotoxicity in the rat. Regulatory Toxicology and Pharmacology, 2017, 84, 35-44.	2.7	16
58	Pharmacological Interventions to Prevent Vascular Endothelial Dysfunction: Future Directions. Journal of Health Science, 2008, 54, 1-16.	0.9	15
59	The Defensive Effect of Benfotiamine in Sodium Arsenite-Induced Experimental Vascular Endothelial Dysfunction. Biological Trace Element Research, 2010, 137, 96-109.	3.5	15
60	Modulation of cardioprotective effect of ischemic pre- and postconditioning in the hyperhomocysteinemic rat heart. Methods and Findings in Experimental and Clinical Pharmacology, 2009, 31, 71.	0.8	15
61	Experimental Models for Vascular Endothelial Dysfunction. Trends in Medical Research, 2007, 2, 12-20.	0.2	15
62	Possible involvement of PPARÎ³-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities. Molecular and Cellular Biochemistry, 2013, 374, 61-72.	3.1	14
63	Chronic oral administration of lowâ€dose combination of fenofibrate and rosuvastatin protects the rat heart against experimentally induced acute myocardial infarction. Fundamental and Clinical Pharmacology, 2016, 30, 394-405.	1.9	14
64	Renin-angiotensin-aldosterone: An inclusive, an invigorative, an interactive and an interminable system. Pharmacological Research, 2017, 125, 1-3.	7.1	14
65	Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management. Pharmacological Research, 2021, 174, 105916.	7.1	14
66	How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?. Cellular Signalling, 2012, 24, 1583-1591.	3.6	13
67	Fenofibrate attenuates impaired ischemic preconditioning-mediated cardioprotection in the fructose-fed hypertriglyceridemic rat heart. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 319-329.	3.0	13
68	The critical steps for successful research: The research proposal and scientific writing. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, 130-138.	0.4	13
69	Adenosine-A1 Receptors Activation Restores the Suppressed Cardioprotective Effects of Ischemic Preconditioning in Hyperhomocysteinemic Rat Hearts. Journal of Cardiovascular Pharmacology, 2009, 54, 204-212.	1.9	11
70	Possible Role of JAK-2 in Attenuated Cardioprotective Effect of Ischemic Preconditioning in Hyperhomocysteinemic Rat Hearts. Yakugaku Zasshi, 2009, 129, 523-535.	0.2	11
71	The physiologic and physiopathologic roles of perivascular adipose tissue and its interactions with blood vessels and the renin-angiotensin system. Pharmacological Research, 2021, 173, 105890.	7.1	11
72	Hyperhomocysteinemia and Cardiovascular Disorders: Is There a Correlation?. Trends in Medical Research, 2007, 2, 160-166.	0.2	11

#	Article	IF	Citations
73	The combined strategy with PPARÎ± agonism and AT1 receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat. Pharmacological Research, 2012, 66, 349-356.	7.1	10
74	Fish Oil Blunted Nicotine-Induced Vascular Endothelial Abnormalities Possibly via Activation of PPARÎ³-eNOS-NO Signals. Cardiovascular Toxicology, 2013, 13, 110-122.	2.7	10
75	Novel Use of Uric Acid and Sodium Arsenite to Induce Vascular Endothelial Dysfunction in Rats. Journal of Pharmacology and Toxicology, 2007, 2, 437-446.	0.2	9
76	EDITORIAL [Hot Topic-II: PPAR Ligands and Cardiovascular Disorders: Friend or Foe (Guest Editors:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.5	7
77	Unraveling the Differentially Articulated Axes of the Century-Old Reninâ€"Angiotensinâ€"Aldosterone System: Potential Therapeutic Implications. Cardiovascular Toxicology, 2022, 22, 246-253.	2.7	7
78	The infarct size-limiting effect of ischemic postconditioning (IPOC) is suppressed in isolated hyperhomocysteinemic (Hhcy) rat hearts: The reasonable role of PKC-Î´. Biomedicine and Pharmacotherapy, 2009, 63, 787-791.	5.6	6
79	Hyperuricemia: Is it a Risk Factor for Vascular Endothelial Dysfunction and Associated Cardiovascular Disorders?. Current Hypertension Reviews, 2009, 5, 1-6.	0.9	6
80	Peroxisome Proliferator Activated Receptor Agonists: Emerging Therapy for Cardiovascular Complications. Journal of Pharmacology and Toxicology, 2007, 2, 205-219.	0.2	6
81	Effect of edaravone in diabetes mellitus-induced nephropathy in rats. Korean Journal of Physiology and Pharmacology, 2016, 20, 333.	1.2	5
82	The potential modulatory role of curcumin on renal epithelial-to-mesenchymal transition in renal diseases. Pharmacological Research, 2021, 169, 105646.	7.1	3
83	The renin-angiotensin-aldosterone system: A century-old diversified system with several therapeutic avenues. Pharmacological Research, 2021, 174, 105929.	7.1	3
84	Multifaceted cardiac signal transduction mediated by G protein-coupled receptors: Potential target sites where an unambiguous attention is needed for exploring new drugs for cardiovascular disorders. Biomedicine and Aging Pathology, 2011, 1, 197-202.	0.8	2
85	Drugs Targeting RAAS in the Treatment of Hypertension and Other Cardiovascular Diseases. , 2015, , 751-806.		2
86	Effect of Fenofibrate in Pressure Overload-induced Experimental Cardiac Hypertrophy. International Journal of Biological Chemistry, 2007, 1, 104-110.	0.3	2
87	Is hypertriglyceridemia a key detrimental factor or associative triggering factor for cardiovascular abnormalities?. Systematic Reviews in Pharmacy (discontinued), 2012, 3, 1.	0.2	0